Vorinostat Can Reduce an Ongoing Fibrosis and Preserve Key Liver Metabolic Functions by Selectively Altering Mesenchymal Cell Differentiation
Vorinostat Can Reduce an Ongoing Fibrosis and Preserve Key Liver Metabolic Functions by Selectively Altering Mesenchymal Cell Differentiation
GUAN, Y.; Peltz, G.
AbstractLiver fibrosis is a major global cause of mortality that is driven by the activation of hepatic stellate cells (HSCs) into extracellular matrix (ECM)-producing myofibroblasts (MyoFs). The lack of predictive human in vitro models has severely hampered the discovery of targeted anti-fibrotic therapies. Here, we describe a human iPSC-derived hepatic micro-organoid (microHO) model, which labels collagen producing cells, to study liver fibrosis pathophysiology and screen drug candidates. We discovered that while multiple drugs prevented fibrosis when co-administered prophylactically with TGF{beta}1, only the FDA-approved pan-HDAC inhibitor Vorinostat (SAHA) successfully reduced an established, ongoing fibrosis and preserved life-sustaining liver metabolic functions in a fibrotic microenvironment, including ammonia detoxification and CYP3A4-mediated drug metabolism. To uncover its mechanism of action, we utilized single-cell RNA sequencing and CRISPR-Cas12a lineage tracing. We found that Vorinostat actively redirects HSC differentiation away from pro-fibrotic MyoFs and toward a distinct, fibrosis-suppressing mesenchymal inhibitory (MesInh) cell. By reversing TGF{beta}1-induced epigenetic silencing, Vorinostat opens condensed chromatin to rescue metabolic gene expression and generates anti-fibrotic effectors that neutralize ongoing TGF{beta}1 signaling. Given its distinct capacity to remodel mesenchymal cell fate and reverse epigenetic repression of metabolic genes at clinically achievable concentrations, Vorinostat represents a highly promising drug for repurposing as a therapeutic for advanced human liver fibrosis.